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INTRODUCTION
Lung cancer is the most common cause of cancer death
in Japanese males, with approximately 70,000 new cases
reported in 1996. There is currently no doubt that the use
of tobacco products is the single most important causative
factor in the development of lung cancer, although other
environmental factors including air pollution may play a
role. While the past 20 years has not yielded significant
improvements in the diagnosis or treatment of lung
cancer, this period has experienced an extraordinary
expansion in the understanding of the molecular
oncogenesis of lung cancer (1, 2). Investigations have
strongly supported a multistep mechanism of tumor
initiation and progression, induced by gene alterations
(Fig.1). One search for a genetic basis of lung cancer has
involved studies of alterations in the expression of certain
dominant oncogenes or proto-oncogenes such as myc and
ras gene family members (3-8). Activation of dominant
oncogenes (by gene amplification, rearrangements, or
somatic mutations) occurs in a number of bronchial
epithelial cells. Another search for genetic causes of
lung cancer has been the clarification of chromosomal
deletions present in lung cancer cells, and the subsequent
use of this information to identify cellular genes that
locate at those regions and that might function in what has
been referred to as tumor suppressor genes or recessive
oncogenes (9-12), which is the main theme of this review
article.
The concept of human tumor suppressor gene has
its origins in the paradigm of familial childhood tumors
such as Wilm's tumor and familial retinoblastoma.
Although family studies of kindreds susceptible to these
tumors demonstrated a dominant Mendelian pattern
of inheritance, a recessive model of tumorigenesis
was postulated by Knudson in 1971 (13, 14). In the
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Fig.1. Multistep genetic model for lung cancer. Each step (solid
arrow)progresses by somatic mutations(occurring from carcinogen
exposure) or autocrine/paracrine effects of growth factors.
Somatic mutations include chromosomal deletion, chromosomal
rearrangement, subtle structural mutation, and gene amplification.
These somatic mutations activate dominant oncogenes (ras, myc,
others) or inactivate tumor suppressor genes (Rb , P53 , P16 ,
putative tumor suppressor gene at chromosome 3p, others).
Received for publication June 20, 1997 ; accepted July 31, 1997.
１ Address correspondence and reprint requests to Eiji Shimizu, M.D.,
Ph.D., Third Department of Internal Medicine, The University of Tokushima
School of Medicine, 3-18-15, Kuramoto-cho, Tokushima, Japan.
The Journal of Medical Investigation Vol.44 1997
１５
case of retinoblastoma, epidemiologic data suggested
there was the clinical difference between the familial
and the sporadic forms of retinoblastoma. In familial
retinoblastoma, retinal tumors developed earlier (occa-
sionally present at birth) than in sporadic retinoblastoma.
In addition, on average three foci of tumor were identified
in patients with the familial retinoblastoma (often
resulting in bilateral disease), whereas in patients with
sporadic retinoblastoma, only one focus of tumor
was observed. Based on these observations, Knudson
proposed the existence of a retinoblastoma susceptibility
gene (Rb) , and he proposed that one allele of this gene
is inactivated in the germ-line cells of patients with
familial retinoblastoma (Fig.2). The germ-line inactivation
could have been inherited from one of the parents or
could have arisen de novo during embryogenesis. The
result is that every cell in that case would have one
inactivated allele of the Rb gene ; however, such cells
would be otherwise phenotypically normal. Only one
somatic mutation in the remaining allele of the Rb gene
would be required to inactivate gene expression and
consequently result in tumor formation in retina. In
contrast, in sporadic cases, two independent somatic
mutations would have to occur in the same gene and in
the same cell. The probability of this event would be much
less likely, thus accounting for the later onset and the
finding of only one focus of retinal tumor. This hypothesis
was supported several years later with the identification of
cytogenetic abnormalities at chromosome 13q14 in a small
percentage of patients with familial retinoblastoma (15).
This was confirmed and expanded to a large proportion of
retinoblastoma cases when more sensitive techniques
including restriction fragment length polymorphism
(RFLP) were employed to test for subtle chromosomal
deletions at the molecular level (16). This indirect
evidence further supported the possibility of an Rb gene
whose tumorigenic potential would be unmasked by its
inactivation through structural mutations such as a
deletion. Finally, in 1986 and 1987, three groups (17-19)
identified a cDNA encoding a gene at chromosome 13q14
with characteristics of a retinoblastoma susceptibility gene
as initially predicted by Knudson. Subsequently, several
tumor suppressor genes have been found to be mutated
and inactivated in hereditary cancer-prone disorders
(Table 1).
CHARACTERISTICS OF SMALL CELL LUNG
CANCER (SCLC) AND NON-SMALL CELL
LUNG CANCER (NSCLC)
Lung cancer has been conveniently separated into two
major categories (designated as small cell or non-small
cell lung cancer) on the basis of clinical behavior and
histologic appearance under light microscopy (Table 2)
(19-23). Small cell lung cancer (SCLC) constitutes about
20% of all cases of lung cancer and is an aggressive lung
tumor with a high propensity for disseminated spread
throughout the body. As a result, surgical resections of
SCLC are rare, limiting the ability of the investigator to
obtain primary tumor sample. Although SCLCs are
initially sensitive to anticancer chemotherapy and/or
radiotherapy, with a tumor reduction seen in almost
all treated cases, the disease usually recurs, at which
time it is usually resistant to any further treatments.
The appearance of SCLC as a small cell with pyknotic
nuclei (oat cell or lymphocytic appearance) is likely a
crush artifact from the bronchoscopic biopsy, while
well-preserved tissue sections show larger epithelial cells
with a fine nuclear chromatin pattern. Nonetheless, the
histologic appearance of SCLC is characteristic and
remains the only finding to establish the diagnosis.
A major advance in the study of the biology of
lung cancers was the ability to generate many continuous
cell lines derived from biopsies of patients with lung
cancer. Cell lines obtained from SCLC specimens
characteristically grow as tight clusters of 20 to
several hundred cells that nonadherently float in liquid
culture medium, making it difficult to obtain viable
single cell suspensions (Fig.3) (23). Early biochemical
investigations confirmed the observation that SCLC is a
neuroendocrine tumor characterized by neurosecretory
granules and the production of several neuron-specific
enzymes and peptides, including dopa-decarboxylase
Fig. 2. Two-hit model for tumor suppressor genes. A mutation
resulting in the inactivation of a tumor suppressor gene,
represented by a closed square. Sporadic tumors evolve from the
clonal expansion of a cell that has undergone two independent
somatic (aquired) mutations, while familial tumors require only a
single somatic mutation in the remaining allele.
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(DDC), neuron-specific enolase (NSE),
the brain isoenzyme of creatine kinase
(CK-BB), chromogranin A, bombesin-like
immunoreactivity or gastrin releasing peptide
(GRP), adrenocorticotropic hormone (ACTH),
anti-diuretic hormone (ADH), atrial natriuretic
peptide (ANP), and others (Table 2) (20-
24). The biologic significance of the
production of functionally active enzymes
such as enolase and creatine kinase is
unknown. However, the expression of
other products, such as GRP, has been
speculated to play a mitogenic role in an
autocrine mechanism. In summary, these
immortalized cell lines have continued to
serve as a valuable resource for biochemical
and cytogenetic studies that have ushered
in the first discovery of genetic alterations in
lung cancer.
Non-small cell lung cancer (NSCLC)
includes all other types of lung cancer and,
as a result, is a collection of at least four
histologic types : squamous cell carcinoma,
bronchioloalveolar and adenocarcinoma,
large cell carcinoma, and undifferentiated
lung carcinoma (24). Although NSCLCs are
less likely than SCLCs to undergo early
dissemination, they are characterized by
aggressive local spread and are less
responsive to anticancer chemotherapy
and/or radiotherapy (24). Namely, NSCLC
patients are more likely to undergo surgical
treatment, allowing the collection of primary
tumor specimens for laboratory investigations.
In addition, tumorigenic cell lines can also
be derived from these samples and such cultures typically
grow as an adherent monolayer with fibroblast-like
morphology (Fig.3) (23). Although this classification of
SCLC vs. NSCLC has been useful for both pathologists
and clinicians, it incorrectly implies an understanding of
the cell of origin of these cancers. Generally, it is believed
that SCLCs arise from rare cells with neural APUD (amine
precursor uptake and decarboxylation) features that are
buried in the bronchial mucosa, while NSCLCs arise from
other precommitted bronchial epithelial cells. For many
years, however, pathologist have observed lung cancers
characterized by admixtures of both SCLC and NSCLC
histology. Furthermore, about 10-15% of NSCLCs produce
neuroendocrine enzymes and peptides (24). These
observations have raised the hypothesis (unitarian theory
of lung cancer) of a single progenitor cell that gives rise to
different types of lung cancers. However, the molecular
genetic analysis of SCLC and NSCLC tumors has revealed
as many similarities as differences between the two
histologic types, and at present medical oncologists will
continue to use the same pathology-based classification
system.Fig. 3. Appearance of several lung cancer cell lines in liquid culture
by inverted microscopy : Non-small cell lung cancer (NSCLC) lines
(A : Ma-44, B : Ma-31, C : Ma-29) and small cell lung cancer (SCLC)
lines(D : N417, E : Ms-10, F : H69)
Table 1. Hereditary tumors and affected genes
Table 2. Characteristics of SCLC and NSCLC
SCLC, small cell lung cancer ; NSCLC, non-small cell lung cancer ; L-DCC, L-dopa
decarboxylase ; NSE, neuron-specific enolase ; CK-BB, brain isotype of creatine
kinase ; ADH, antidiuretic hormone ; ANP, atrial natriuretic peptide ; GRP, gastrin
releasing peptide
gene chromosomal locus
Retinoblastoma
Wilm's tumor
Familial polyposis coli
Li-Fraumeni syndrome
von Recklinghausen neurofibromatosis
RB1
WT1
APC
P53
NF1
13q
11q
5q
17p
17q
SCLC NSCLC
Clinical
Method of diagnosis
Distribution of cases
Primary treatment
Dissemination at diagnosis
Paraneoplastic syndromes
(Ectopic peptide secretion)
Growth in tissue culture
Biochemical
Neuroendocrine markers
(L-DCC, NSE, Chromogranin
CK-BB, Neurosecretory granules)
Peptide secretion
(ADH, ANP, GRP)
Extracellular matrix production
(Laminin)
Light microscopy
20%
Chemo (Radio) therapy
Frequent
Common
Nonadherent
clusters
Common
Present
Common
Light microscopy
80%
Surgery
Less frequent
Uncommon
Adherent
monolayer
Rare
Absent
Rare
The Journal of Medical Investigation Vol.44 1997 １７
THE RB GENE AND LUNG CANCER
Reviews of cytogenetic data in lung cancer samples
revealed numerous examples of deletions or unbalanced
translocations involving the chromosome band 13q14
present in karyotypes of SCLC cell lines (Table 3) (9, 10,
25-28). These had been previously overlooked due to the
extensive aneuploidy found in SCLC samples, and
this suggests that additional marker chromosome
abnormalities may yet be found. A subsequent review
of RFLP data from primary lung cancer samples
demonstrated frequent loss of heterozygosity, not only
on chromosome 3p, but also on 13q and 17p in SCLC
(11,12). Although SCLC had a completely different
clinical presentation than retinoblastoma, both grow
nonadherently in liquid culture medium as tight clusters,
and both frequently amplify myc family genes (4, 29).
Therefore, the Rb gene, located at chromosome 13q14,
was a potential target for somatic mutations in SCLC.
Early DNA and RNA studies found evidence of
structural mutations in 20% of SCLC samples tested and
absent mRNA in approximately 40% of SCLC cell lines
(30). Furthermore, in each case where a matched primary
cancer sample was available, the abnormality detected
was identical to that observed from the derived SCLC cell
line (30). Further studies of RB protein revealed that the
majority of SCLC samples that expressed apparently
normal mRNA had no detectable RB protein (31, 32). In
addition, several examples of mutant RB proteins were
found as a result of subtle mutations, generally single
point mutations. To date these have included aberrant
deletion of nucleotide sequences from exons 16, 21, or 22,
yielding stable, but truncated, proteins with intact
amino- and carboxyl-terminal residues (32, 33). Some of
these same alterations have been observed in other tumor
types, such as a deletion of exon 21, which was reported
in both a bladder cancer and a prostate cancer, while an
example of a deletion of exon 22 has also been seen in a
case of NSCLC. Another interesting mutation identified in
SCLC was a single nucleotide change in exon 21 that led
to a missense mutation (cys706 to phe706)(34). Each of these
in vivo RB protein mutants share the same phenotype :
they are defective in viral oncoprotein binding (and,
therefore, also defective in their ability to bind to the
corresponding cellular RB binding proteins such as E2F)
and in phosphorylation (Fig.4) (35). The mutations do
not directly affect a cluster of serine and threonine
residues that are the presumed sites of phosphorylation,
these mutations, but instead, appear to block a specific
conformation required for protein binding and
phosphorylation. The in vivo RB mutants, therefore, are
presumed to be inactive (loss of function mutants), and
this is consistent with their inability to transform primary
rat embryo cells by themselves or in cooperation with an
activated ras gene (36).
In summary, almost all SCLC samples (>90%) have
absent or aberrant RB protein expression (31, 32, 37). In
contrast, only about 15% of NSCLC samples have
inactivated RB function (31, 32, 37). RB protein status in
lung cancer, extrapulmonary small cell carcinoma, and
mesothelioma from American and Japanese patients is
shown in Table 4 (37, 38). This lower frequency of Rb
inactivation is seen in a wide range of adult tumors, such
as bladder, prostate, breast, and hematologic tumors. The
biologic significance of the Rb gene as a high-frequency
target in SCLC, and a lower frequency target in other
common tumors, is still unclear.
Reintroduction of the Rb gene in a variety of Rb -1- cell
lines, such as retinoblastoma, osteosarcoma, prostate, and
bladder cancer derived cell lines, has resulted in complete
or partial suppression of tumorigenicity when measured
as the ability to form subcutaneous tumors in nude mice
(24). Two studies have demonstrated similar findings in
both NSCLC and SCLC cell lines (39, 40). Similar to the
findings reported in prostate and bladder cancer,
Table 3. Cytogenetic abnormalities in SCLC and NSCLC
SCLC, small cell lung cancer ; NSCLC, non-small cell lung cancer.
Fig. 4. RB protein expression of lung cancer cells by western
blotting. Lanes : 1, N417 SCLC ; 2, H209 SCLC ; 3, Ma-31 NSCLC.
RB protein from N417 cells (lane 1) was not detected. RB protein
derived from H209 cells (lane 2) was a dephosphorylated type that
migrated as a single band at 105 kDa, indicating that the protein
was mutant. The protein that was defective in phosphorylation and
in oncoprotein binding such as adenoviral E1A and SV40 large T
antigen, was identified as having a point mutation within exon 21
resulting in a single cysteine to phenylalanine substitution at codon
706. RB protein derived from Ma-31 cells (lane 3) exhibited
differently phosphorylated species that migrated at 105～110 kDa
on 7.5% SDS/PAGE, indicating that the protein was the wildtype.
Table 4. Altered RB protein expression (absent or mutant) in
SCLC, NSCLC, extrapulmonary small cell carcinoma (EPSC),
pulmonary carcinoid, and mesothelioma cell lines derived from
American and Japanese patients
SCLC NSCLC
3p14-3p24
13q14
17p
11p
1p
5q
3p21-3p25
3p14
i (3q)
11p
17p
1q1-1q3
9p
17q
19q13
5q1
7q
SCLC EPSC carcinoid NSCLC mesothelioma
USA
Japan
67/76
10/13
4/5 1/6 12/81
1/15
0/4
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however, the suppression was not complete ; some
mice developed tumors following injection with cells
reexpressing Rb gene, although these were up to 10 times
smaller than the corresponding tumors in the same mice
following injection with the same parent cell line injected
with plasmid alone. In lung cancer cells, the reexpression
of a functional Rb gene can result in tumor suppression in
vivo , but the effect appears to be variable. This probably
reflects the multiple genetic abnormalities accumulated in
lung cancer cells. This accumulation of genetic defects
contrasts to familial retinoblastoma, which results from
the disruption of a single locus, the Rb gene. Interestingly,
the Rb -mediated tumor-suppressive effect can be totally
reversed in lung cancer cells by co-injection with an
extract of an extracellular matrix (40). The capacity for
Rb -mediated tumor suppression to be overcome by
tissue-specific factors may also explain the inability of Rb
reexpression to exert a tumor-suppressive effect on
retinoblastoma cells following intraocular injection in
athymic mice (41).
The presence of a disruption of the Rb locus in almost
all SCLC cell lines and a significant number of NSCLC
cell lines and tumor samples clearly indicates a central
role for the RB protein in both cell growth regulation and
molecular carcinogenesis. Although alterations of Rb gene
expression have been implicated as a negative prognostic
factor in both sarcomas and bladder carcinomas, similar
implications in lung cancer are not established (Table 5)
(37, 42-45). However, there have been recent reports
of decreased survival in early-stage NSCLC with Rb
gene abnormalities and a higher incidence of Rb
gene abnormalities in stage  and  NSCLC tumor
specimens. When RB protein status is combined with
analysis of P53 status, there is an increased survival
advantage of 34 months (12 months vs. 46 months,
P<0.001) in stage and NSCLC (46). The current lack
of effective chemotherapeutic agents in NSCLC and
chemoresistant SCLC makes clinical application of
survival data in lung cancer difficult (47-52). However,
with improved methods (adenoviral vector) of gene
transfer for pulmonary disease such as cystic fibrosis and
pulmonary emphysema, there exists a possible future role
for the use of the Rb gene in directed gene therapy in lung
cancers.
THE P53 GENE AND LUNG CANCER
The P53 gene encodes a 53 kDa nuclear protein that
localizes to chromosome 17p13. It was originally identified
as a host cellular protein that bound to the large T viral
antigen of animal cells infected with simian virus 40 (SV
40) (53, 54), and those early reports speculated that the
large T antigen exerts its transforming effect by binding to
and, therefore modulating, the activity of the cellular P53
gene (53). Several years later, however, it was classified as
a dominant oncogene on the basis of elevated protein
levels in many tumors and the ability of its cDNA
to transform primary rat embryo fibroblasts when
transfected in cooperation with an activated ras gene
(55). In 1988, however, it was recognized that all
transforming clones of P53 had undergone activating
somatic mutations, while, in contrast, wild-type P53
appeared to exert a phenotype of growth suppression
when transfected into immortalized cell lines (56).
Furthermore, the elevated levels of P53 protein observed
in many tumors were the result of mutations that markdly
increased the protein half-life, and the detection of
increased protein levels on western blotting is one of the
methods used to screen samples for the presence of
activating P53 mutations.
Earlier RFLP analyses had implicated tumor-specific
loss of heterozygosity on chromosome 17p in both lung
cancer and colon cancer (12). Shortly afterward it was
demonstrated that the gene on 17p targeted for allele loss
in colon cancer was the P53 gene. Similar investigations of
lung cancer revealed that essentially all (70-100%) SCLCs
have aquired mutations, while approximately 50% of
NSCLCs show evidence of P53 mutations (57). The P53
mutations are distributed throughout the open-reading
frame. The majority of mutations are substitutions of one
amino acid residue for another at a single codon, but
frame shifts, insertions, deletions, and splicing mutations
have been also reported (58). P53 is composed of 11
exons, and the majority of mutations are found in the
central exons, exons 5 through 8. As in Rb mutations
observed in lung cancer, G-to-T transitions characteristic
of tobacco-induced mutations have been seen in P53
mutations characterized from lung cancer specimens or
cell lines (59). These findings suggest the need for an
objective assay to identify exogenous and endogenous
carcinogens acting on individual humans.
THE P16 GENE AND LUNG CANCER
The P16 (INK4A, MTS1) has been identified as a
candidate for the familial melanoma gene at
chromosome 9p21, and germ line mutations in the
MTS1 have been identified in several kindreds
with familial melanoma (60). In addition, aquired
mutations have been identified in a variety
of transformed cell lines and several primary
tumors (60). Inactivation of the RB protein by
phosphorylation is mediated by a family of cyclins
and cyclin-dependent kinases (CDKs), and
inhibited by CDK inhibitors. P16 has kinase
Table 5. Prognostic significance of RB alteration
IHC ; immunohistochemistry, IB ; immunoblot, NB ; Northern blot,
SB ; Southern blot, NS ; not significant.
Tumor Sample Method Altered RB
on survival
Sarcoma
Bladder
Bladder
NSCLC
NSCLC
SCLC
56 fresh tumors
48 fresh tumors
43 fresh tumors
194 fresh tumors
68 cell lines
62 cell lines
IHC, IB
IHC
IHC
IHC, NB, SB
IB
IB
Worse
Worse
Worse
NS
NS
NS
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inhibitor activity that is specific for CDK4 and is a strong
inhibitor in vitro for RB protein phosphorylation (61). An
interesting observation is that lung cancer cell lines that
are RB-positive without inactivating Rb mutations
are almost invariably P16-negative when examined by
immunoblotting (Table 6) (62, 63). In summary, in only
10% of SCLC samples is P16 protein expression absent,
while 70% of NSCLC samples have loss of P16.
OTHER TUMOR SUPPRESSOR GENES
The accuracy with which cytogenetics and RFLP
analyses predicted the presence of tumor suppressor
genes at the 13q (Rb), 17p (P53), and 9p (P16) regions
suggests that evidence for the presence of nonrandom,
tumor-specific allele loss is an important clue for the
identification of additional tumor suppressor genes. Many
other chromosomal loci have been identified as frequent
sites for gross structural mutations in lung cancer (Table
3) (9, 10, 25-28), suggesting that many of these sites also
harbor novel genes playing a role in normal growth and
development for pulmonary tissues. Although all
karyotypes demonstrated multiple alterations, the most
consistent abnormality was a deletional event on the short
arm of chromosome 3, and more precise cytogenetics
allowed the smallest consensus deletion to be mapped to
the region of 3p14-3p24. This finding was tested by RFLP
analyses of both primary SCLCs and NSCLCs (12). These
investigators verified that there was evidence at the
molecular level for DNA loss on one allele of 3p in more
than 90% of SCLCs, while a similar allelic loss was
observed in approximately 50% of NSCLC samples.
The consistent finding of tumor-specific chromosomal
deletions in this region led to the hypothesis that a lung
cancer susceptibility gene located at this area. One
approach to identify a putative 3p tumor suppressor gene
has been to examine interesting genes that have
previously been characterized and mapped to this region.
Several candidate genes have been studied, including the
thyroid hormone receptor (c-erbΑ-β), a retinoic acid
receptor (rarβ), and tyrosine phosphatase (PTP-λ) (24).
Although each of these genes undergo allelic loss in most
tumor samples from patients with SCLC, evidence for
homozygous mutations and/or loss of wild-type protein
function has not been reported for these cases. Attempts
to identify the putative tumor suppressor gene on 3p have
not been successful to date.
The Rb gene encodes an 105-kDa nuclear
phosphoprotein. The gene product is a substrate
for the cyclin-dependent kinases (CDKs) and is
phosphorylated in a cell-cycle-dependent manner
(64-67). To fully understand the importance of
the Rb gene product in the regulation of the
cell cycle, proteins involved in cell cycle
regulation are necessary (68). The schema of
the role of tumor suppressor proteins in cell cycle
regulation is shown in Fig.5. The resting or nondividing
cell (G0) is characterized by the presence of
hypophosphorylated RB protein. The signals that maintain
the cell in the resting phase are complex but include a
variety of exogenous growth factors. The mitogenic
stimuli result in a cellular commitment in late G1 to
undergo DNA replication, or enter S phase (69-71). This
check-point is the equivalent of the G1 decision point in
budding yeast known as START. After the restriction to
enter S-phase has passed, the cell is committed to DNA
replication under the influence of the cyclins and their
associated CDKs, which are further subject to regulation
Table 6. Summary of P16 and RB status in 88 lung cancer cell lines
+ wild-type ; - absent ; mt mutant.
Fig.5. The cell cycle and tumor suppressor proteins. RB
protein and other RB family members (p107, p130) remain
hypophosphorylated in the quiescent (G0/G1) cell. As cyclin D
levels rise in response to mitogenic stimuli, the cyclin D-associated
CDKs (CDK2, CDK4) target RB for hyper-phosphorylation. The
cell commits to DNA replication (S-phase) following a rise in cyclin
E levels, and also interacts with the CDK family members to target
RB for further phosphorylation. RB remains phosphorylated
until late G2, when phosphatase activity leads to specific RB
dephosphorylation. The CDK inhibitors (p16, p21) act to repress
kinase activity of the CDK family members. DNA damage, induced
by radiation/chemotherapy, transcriptionally activates p21 via
wild-type p53.
TUMOR SUPPRESSOR GENE PRODUCTS
AND CELL CYCLE REGULATIONP16 ( + ) P16 (‐) total
SCLC RB( + )
RB(‐) or (mt)
１（１４％）
４８（１００％）
６（８６％）
０（０％）
７
４８
NSCLC RB( + )
RB( + ) or (mt)
４（１５％）
６（８６％）
２２（８５％）
１（１４％）
２６
７
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by a group of CDK inhibitors (72). Following mitogenic
stimulation, eukaryotic cells in late G1 demonstrate a
rapid increase in the levels of the D family cyclins (cyclins
D1, D2, D3) (69-71). The levels of the cyclin D family
members appear to be highly sensitive to the presence of
growth factor stimuli. The D family cyclins associate with
and regulate several CDKs, most specifically CDK2 and
CDK4, positively modulating their kinase activity,
resulting in the phosphorylation of target proteins
possessing canonical kinase sequences. The 105-kDa RB
protein has at least nine phosphorylation target motifs in
its primary amino acid sequence and is a cellular substrate
for the CDK system. Although cyclin D-mediated RB
hyper-phosphorylation is an important early response to
mitogenic stimuli, the rate limiting factor in determining
the G1/S-phase transition appears to be cyclin E protein
levels, which begin to rise in late G 1. Cyclin E associates
with CDK2 and probably plays a role in mediating
additional RB hyperphosphorylation. Overexpression
of members of the E, D, and A family of cyclins has
been demonstrated to overcome RB-mediated growth
suppression (73), demonstrating a possible role for these
cyclins in regulating in vivo RB function.
As the cells enter S-phase, there is progressive
phosphorylation at a series of serine and threonine
residues identified as target residues of the CDK system
(68). During G2 phase, the RB protein remains in a
hyperphosphorylated state until specific phosphatase
activity dephosphorylates the protein as it reenters G1/
G0. The capacity to serve as a target for phosphorylation
by the CDKs is one of several critical functional properties
that is lost in mutant forms of the RB protein identified
from transformed cell lines. This loss of the wild-type RB
phenotype can easily be identified by immunoblotting.
Conventionally, wild-type RB protein isolated from
asynchronously growing cells migrates as a series of
bands varying in size form 105 to 110 kDa. The slower
migrating bands represent the hyperphosphorylated
forms of RB protein. In contrast, mutant forms of the RB
protein migrate as a single band, representing exclusively
the hypophosphorylated RB moiety (Fig.4). As the cell
progresses through the cell cycle, these mutant forms of
the RB protein remain hypophosphorylated, in contrast to
normal wild-type cell cycle fluctuations (32-35).
The molecular significance of the CDK system and its
role in RB phosphorylation are further emphasized by an
important class of identified and cloned CDK inhibitors,
P16, P21 (WAF1, SDI1, CIP1), and P27 (KIP1) (68).
These factors play a role in regulating the activity of the
various CDK members, in essence functioning as a
check on the proliferative signal that is the result of
cyclin-mediated CDK activation. As negative controlling
elements of the cell cycle, these inhibitors are themselves
strong candidates of tumor suppressor genes. P21 is
transcriptionally activated by P53 (72). P21 binds to
cyclins A, D1, E, and CDK2 and is a potent inhibitor of the
CDKs and RB phosphorylation. Expression of this gene
thus directly inhibits cell cycle progression, and loss of
expression via inactivation of the transcriptional activity of
P53 would directly cause loss of cell cycle regulation. P21
provides a link between the functional roles of P53 and
RB. P21 thus appears to be a direct mediator of
growth-suppressive properties of P53.
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